OBJECTIVES: Among persons in current HIV outpatient care, data on opioid prescribing are lacking. This study aims to evaluate predictors of repeat opioid prescribing and to characterize outpatient opioid prescribing practices. METHODS: Retrospective cross-sectional study of persons ≥18 years in HIV outpatient care who completed an annual behavioral assessment between June 2008 and June 2009. Persons were grouped by ≤1 and ≥2 opioid prescriptions (no-repeat-opioid and repeat-opioids, respectively). Independent predictors for repeat-opioids were evaluated. Opioid prescribing practices were characterized in a sub-study of persons prescribed any opioid. RESULTS: Overall, 659 persons were included, median age 43 years, 70% men, and 68% African American. Independent predictors of repeat-opioids (88 [13%] persons) included opportunistic illnesses (both current and previous), depression, peripheral neuropathy, and hepatitis C coinfection (P<0.05). In the subgroup, 140 persons received any opioid prescription (96% short-acting, 33% tramadol). Indications for opioid prescribing were obtained in 101 (72%) persons, with 97% for noncancer-related pain symptoms. Therapeutic response was documented on follow-up in 67 (48%) persons, with no subjective relief of symptoms in 63%. Urine drug screens were requested in 6 (4%) persons, and all performed were positive for illicit drugs. CONCLUSIONS: Advanced HIV disease and greater medical and neuropsychiatric comorbidity predict repeat opioid prescribing, and these findings reflect the underlying complexities in managing pain symptoms in this population. We also highlight multiple deficiencies in opioid prescribing practices and nonadherence to guidelines, which are of concern as effective and safe pain management for our HIV-infected population is an optimal goal.
OBJECTIVES: Among persons in current HIV outpatient care, data on opioid prescribing are lacking. This study aims to evaluate predictors of repeat opioid prescribing and to characterize outpatient opioid prescribing practices. METHODS: Retrospective cross-sectional study of persons ≥18 years in HIV outpatient care who completed an annual behavioral assessment between June 2008 and June 2009. Persons were grouped by ≤1 and ≥2 opioid prescriptions (no-repeat-opioid and repeat-opioids, respectively). Independent predictors for repeat-opioids were evaluated. Opioid prescribing practices were characterized in a sub-study of persons prescribed any opioid. RESULTS: Overall, 659 persons were included, median age 43 years, 70% men, and 68% African American. Independent predictors of repeat-opioids (88 [13%] persons) included opportunistic illnesses (both current and previous), depression, peripheral neuropathy, and hepatitis C coinfection (P<0.05). In the subgroup, 140 persons received any opioid prescription (96% short-acting, 33% tramadol). Indications for opioid prescribing were obtained in 101 (72%) persons, with 97% for noncancer-related pain symptoms. Therapeutic response was documented on follow-up in 67 (48%) persons, with no subjective relief of symptoms in 63%. Urine drug screens were requested in 6 (4%) persons, and all performed were positive for illicit drugs. CONCLUSIONS:Advanced HIV disease and greater medical and neuropsychiatric comorbidity predict repeat opioid prescribing, and these findings reflect the underlying complexities in managing pain symptoms in this population. We also highlight multiple deficiencies in opioid prescribing practices and nonadherence to guidelines, which are of concern as effective and safe pain management for our HIV-infected population is an optimal goal.
Authors: Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells Journal: Mayo Clin Proc Date: 2010-03 Impact factor: 7.616
Authors: Ned C Sacktor; Matthew Wong; Noeline Nakasujja; Richard L Skolasky; Ola A Selnes; Seggane Musisi; Kevin Robertson; Justin C McArthur; Allan Ronald; Elly Katabira Journal: AIDS Date: 2005-09-02 Impact factor: 4.177
Authors: Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Daniel F Weisberg; Amy C Justice; David A Fiellin Journal: J Pain Date: 2014-08-23 Impact factor: 5.820
Authors: Lisa A Uebelacker; Risa B Weisberg; Debra S Herman; Genie L Bailey; Megan M Pinkston-Camp; Michael D Stein Journal: Pain Med Date: 2015-06-27 Impact factor: 3.750
Authors: E Jennifer Edelman; Kirsha Gordon; William C Becker; Joseph L Goulet; Melissa Skanderson; Julie R Gaither; Jennifer Brennan Braden; Adam J Gordon; Robert D Kerns; Amy C Justice; David A Fiellin Journal: J Gen Intern Med Date: 2012-08-16 Impact factor: 5.128
Authors: Jessica S Merlin; Andrew O Westfall; James L Raper; Anne Zinski; Wynne E Norton; James H Willig; Robert Gross; Christine S Ritchie; Michael S Saag; Michael J Mugavero Journal: J Acquir Immune Defic Syndr Date: 2012-10-01 Impact factor: 3.731
Authors: E J Edelman; K S Gordon; J P Tate; W C Becker; K Bryant; K Crothers; J R Gaither; C L Gibert; A J Gordon; Bdl Marshall; M C Rodriguez-Barradas; J H Samet; M Skanderson; A C Justice; D A Fiellin Journal: HIV Med Date: 2016-11 Impact factor: 3.180
Authors: Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Amy C Justice; David A Fiellin Journal: J Addict Med Date: 2016 Nov/Dec Impact factor: 3.702
Authors: Julie R Gaither; Joseph L Goulet; William C Becker; Stephen Crystal; E Jennifer Edelman; Kirsha Gordon; Robert D Kerns; David Rimland; Melissa Skanderson; Amy C Justice; David A Fiellin Journal: J Gen Intern Med Date: 2016-05 Impact factor: 5.128